Advertisement
Advertisement
ALNY
Alnylam Pharmaceuticals, Inc.
328.06
USDSponsored
-3.18
-0.96%
Feb 06, 15:59 UTC -5
Closed
After-Market
327.08
-0.98
-0.30%
ALNY Earnings Reports
Positive Surprise Ratio
ALNY beat 21 of 39 last estimates.
54%
Next Report
Next Week
Date of Next Report
Feb 12, 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.20B
/$1.18
Implied change from Q3 25 (Revenue/ EPS)
-4.22%
/-44.08%
Implied change from Q4 24 (Revenue/ EPS)
+101.67%
/-281.54%
Alnylam Pharmaceuticals, Inc. earnings per share and revenue
On Oct 30, 2025, ALNY reported earnings of 2.11 USD per share (EPS) for Q3 25, beating the estimate of 0.76 USD, resulting in a 177.16% surprise. Revenue reached 1.25 billion, compared to an expected 997.35 million, with a 25.23% difference. The market reacted with a -6.65% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 28 analysts forecast an EPS of 1.18 USD, with revenue projected to reach 1.20 billion USD, implying an decrease of -44.08% EPS, and decrease of -4.22% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Alnylam Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Alnylam Pharmaceuticals, Inc. reported EPS of $2.11, beating estimates by 177.16%, and revenue of $1.25B, 25.23% above expectations.
How did the market react to Alnylam Pharmaceuticals, Inc.'s Q3 2025 earnings?
The stock price moved down -6.65%, changed from $481.59 before the earnings release to $449.56 the day after.
When is Alnylam Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Feb 12, 2026.
What are the forecasts for Alnylam Pharmaceuticals, Inc.'s next earnings report?
Based on 28
analysts, Alnylam Pharmaceuticals, Inc. is expected to report EPS of $1.18 and revenue of $1.20B for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement